Table 3 Univariate and multivariate analysis of the factors associated with favorable response to antifungal therapy, 100-day survival and overall survival rate
Factors | Favorable response rate | Univ P | Multiv P | 100-day-survival rate | Univ P | Multiv P | OS rate | Univar P | Multiv P |
|---|---|---|---|---|---|---|---|---|---|
Gender | |||||||||
M | 11/21 | 1 | 15/21 | 0.8 | 9/21 | 0.3 | |||
F | 10/19 | 13/19 | 11/19 | ||||||
Age (years) at IA | |||||||||
< the median | 10/20 | 0.8 | 15/20 | 0.5 | 12/20 | 0.2 | |||
≥ the median | 11/20 | 13/20 | 8/20 | ||||||
IA after: | |||||||||
HSCT/Relapse | 12/27 | 0.1 | 17/27 | 0.3 | 10/27 | 0.02 | 0.048 | ||
Diagnosis | 9/13 | 11/13 | 10/13 | ||||||
ANC < 0.5 × 109/l | |||||||||
yes | 16/31 | 1 | 21/31 | 0.7 | 14/31 | 0.5 | |||
no | 5/9 | 7/9 | 6/9 | ||||||
Number of organ affected: | |||||||||
Single organ | 14/29 | 0.4 | 20/29 | 1 | 12/29 | 0.08 | |||
Multiple organs | 7/11 | 8/11 | 8/11 | ||||||
Type of IA | |||||||||
Probable IA | 8/20 | 0.1 | 11/20 | 0.04 | - | 6/20 | 0.01 | ||
Documented IA | 13/20 | 17/20 | 14/20 | ||||||
Surgical treatment | - | ||||||||
Yes | 9/14 | 0.3 | 13/14 | 0.03 | 10/14 | 0.047 | |||
No | 12/26 | 15/26 | 10/26 | ||||||
Timing of caspofungin-based combination therapy | |||||||||
< 7 days from IA | 13/22 | 0.4 | 17/22 | 0.3 | 10/22 | 0.5 | |||
≥ 7 days from IA | 8/18 | 11/18 | 10/18 | ||||||
Combination therapy as: | |||||||||
Primary or | 12/20 | 0.3 | 14/20 | 1 | 10/20 | 1 | |||
Salvage therapy | 9/20 | 14/20 | 10/20 | ||||||
Favorable response | |||||||||
yes | NE | NE | NE | 21/21 | < 0.001 | - | 16/21 | < 0.001 | 0.003 |
no | 7/19 | 4/19 |